Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...

Jefferies analyst Akash Tewari remains bullish on Merck, maintaining a Buy rating and a $138 price target. The firm’s ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Merck & Company (MRK – Research Report). The company’s shares closed yesterday at $80.16. Confi ...

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...